CN103006909B - 一种治疗高血压病组合药物 - Google Patents
一种治疗高血压病组合药物 Download PDFInfo
- Publication number
- CN103006909B CN103006909B CN201210496038.3A CN201210496038A CN103006909B CN 103006909 B CN103006909 B CN 103006909B CN 201210496038 A CN201210496038 A CN 201210496038A CN 103006909 B CN103006909 B CN 103006909B
- Authority
- CN
- China
- Prior art keywords
- parts
- folium
- hypertension
- medicine
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 210000000582 semen Anatomy 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 37
- 241000218628 Ginkgo Species 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 241001077909 Sigesbeckia Species 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 12
- 230000036772 blood pressure Effects 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 230000007812 deficiency Effects 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 230000004438 eyesight Effects 0.000 abstract description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract description 2
- 235000011613 Pinus brutia Nutrition 0.000 abstract description 2
- 241000018646 Pinus brutia Species 0.000 abstract description 2
- 241000722948 Apocynum cannabinum Species 0.000 abstract 1
- 244000104272 Bidens pilosa Species 0.000 abstract 1
- 235000010662 Bidens pilosa Nutrition 0.000 abstract 1
- 241000530115 Clerodendrum trichotomum Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000005426 pharmaceutical component Substances 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 description 13
- 238000001035 drying Methods 0.000 description 8
- 208000007530 Essential hypertension Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000011449 brick Substances 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- -1 polysaccharide glycosides Chemical class 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210496038.3A CN103006909B (zh) | 2012-11-29 | 2012-11-29 | 一种治疗高血压病组合药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210496038.3A CN103006909B (zh) | 2012-11-29 | 2012-11-29 | 一种治疗高血压病组合药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103006909A CN103006909A (zh) | 2013-04-03 |
CN103006909B true CN103006909B (zh) | 2014-09-17 |
Family
ID=47956372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210496038.3A Expired - Fee Related CN103006909B (zh) | 2012-11-29 | 2012-11-29 | 一种治疗高血压病组合药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103006909B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103845379A (zh) * | 2014-03-24 | 2014-06-11 | 张廷盖 | 一种充分发挥药效治疗高血压病的平肝熄风降脂丸 |
CN104306709A (zh) * | 2014-11-20 | 2015-01-28 | 石纯满 | 一种治疗高血压的中药药剂及其制备方法 |
CN111905027B (zh) * | 2020-09-14 | 2021-08-20 | 邝月阁 | 治疗大动脉炎继发高血压的中药组合物及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1129460C (zh) * | 2000-04-04 | 2003-12-03 | 徐代科 | 降压药枕 |
CN1263502C (zh) * | 2004-06-30 | 2006-07-12 | 曹琼 | 一种治疗高血压的中药 |
-
2012
- 2012-11-29 CN CN201210496038.3A patent/CN103006909B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103006909A (zh) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102824393B (zh) | 用于祛风止痛散寒除湿的药物组合物及其制备方法 | |
CN104147577B (zh) | 一种用于促进骨痂生长治疗骨折的膏药 | |
CN105233010A (zh) | 一种补肾壮阳酒及其制备方法 | |
CN103463297B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法和用途 | |
CN103877247B (zh) | 用于治疗褥疮的药物及其制备方法 | |
CN103211930A (zh) | 一种降血脂、降血压的中药制剂 | |
CN103006909B (zh) | 一种治疗高血压病组合药物 | |
CN103990079A (zh) | 用于治疗气滞血瘀型腰肌劳损的药物组合物及其制备方法 | |
CN105343466A (zh) | 一种治疗冠心病的中药组合物 | |
CN102048863A (zh) | 一种治疗腰椎骨质增生的中药 | |
CN104042774A (zh) | 一种治疗骨质疏松症的药物组合物 | |
CN102441131A (zh) | 一种治疗跌打损伤的中药组合物 | |
CN105250569A (zh) | 一种用于治疗末梢神经炎的中药丸剂及制备方法 | |
CN104666999A (zh) | 一种降血压的中药配方 | |
CN104522493A (zh) | 治疗冠状动脉粥样硬化的养生粥及制备方法 | |
CN104606566A (zh) | 一种治疗肝阳上亢型高血压的中药组合物及其制备方法 | |
CN105709169A (zh) | 治疗颈肩腰腿风湿疼痛的药膏 | |
CN101934016A (zh) | 一种治疗关节炎的外用药及其含有矿物质的药膏贴 | |
CN102028887B (zh) | 一种治疗颈椎增生的中药 | |
CN106377623A (zh) | 一种足浴粉 | |
CN104707003B (zh) | 治疗高血压、高血脂的中药胶囊 | |
CN104922631A (zh) | 一种治疗痛经的肚脐贴及其制备方法 | |
CN103933359A (zh) | 用于祛除瘢痕疙瘩的药物组合物及其制备方法 | |
CN104491641A (zh) | 一种促进肌肉拉伤愈合的熏洗药物 | |
CN105477566A (zh) | 一种能减肥排毒的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ding Jinliang Inventor after: Xue Fei Inventor after: Dong Lingjie Inventor after: Ding Dongran Inventor after: Ding Weiran Inventor after: Ding Haoran Inventor before: Ding Jinliang Inventor before: Ding Dongran Inventor before: Ding Weiran Inventor before: Ding Haoran |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: DING JINLIANG DING DONGRAN DING WEIRAN DING HAORAN TO: DING JINLIANG XUE FEI DONG LINGJIE DING DONGRAN DING WEIRAN DING HAORAN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140917 |
|
CF01 | Termination of patent right due to non-payment of annual fee |